[18F]THK-5351

DRUG3 trials

Sponsors

Jae Seung Kim, Asan Foundation, Chang Gung Memorial Hospital

Conditions

Alzheimer DiseaseAlzheimer's DiseaseMild Cognitive ImpairmentNeurodegenerative DiseasesPost-stroke Dementia, Vascular Mild Cognitive Impairment

Phase 1

A Phase I [18F]THK-5351 Positron Emission Tomography Study in Healthy Subjects and Alzheimer's Disease

CompletedNCT03112096

Asan FoundationAlzheimer Disease

Start: 2017-05-17End: 2018-08-31Updated: 2020-12-14

Phase 2

[18F]THK-5351 Positron Emission Computed Tomography Study of Normal, Mild Cognitive Impairment, Alzheimer's Disease and Other Neurodegenerative Disease

CompletedNCT02656498

Jae Seung KimAlzheimer's Disease, Mild Cognitive Impairment, Neurodegenerative Diseases

Start: 2016-01-11End: 2019-12-31Updated: 2020-12-14

The Influence of Sequential Tau Protein and Amyloid Plaque Imaging Changes on Stroke Prognosis and Cognitive Outcome

Chang Gung Memorial HospitalPost-stroke Dementia, Vascular Mild Cognitive Impairment

Start: 2017-06-01End: 2024-05-31Target: 200Updated: 2023-05-06

Related Papers

<sup>18</sup>F-THK5351 PET Positivity and Longitudinal Changes in Cognitive Function in β-Amyloid-Negative Amnestic Mild Cognitive Impairment

Yonsei Medical Journal2022-01-016 citations

Combination of automated brain volumetry on MRI and quantitative tau deposition on THK-5351 PET to support diagnosis of Alzheimer's disease.

2021-05-1413 citations

Intra-individual correlations between quantitative THK-5351 PET and MRI-derived cortical volume in Alzheimer's disease differ according to disease severity and amyloid positivity.

2019-12-135 citations